This application note describes a robust method for detecting somatic mutations from liquid biopsy samples by combining circulating tumor cell (CTC) enrichment with a high sensitivity targeted next-generation sequencing (NGS) panel. The combined workflow has broad implications for how cancer can be monitored non-invasively using a routine blood draw without the need for tissue biopsies. Genomic aberrations detected with this approach can help elucidate the genomic signature of the cancer unique to each patient, and ultimately, can help guide therapeutic decisions.
The IsoFlux™ System (Fluxion Biosciences) enriches rare CTCs from peripheral blood samples and prepares them at high purity for molecular analysis, including NGS. Multiple capture antibodies are employed, including both epithelial and mesenchymal markers, to capture the widest spectrum of CTCs in the circulation. The captured CTCs are lysed and DNA is recovered for genomic analysis.
The Accel-Amplicon™ 56G Oncology Panel (Swift Biosciences) covers 56 clinically-relevant cancer genes in a targeted amplicon format for use with Illumina® sequencers. The panel accommodates low DNA input levels making it ideally suited for liquid biopsy applications.